首页> 外国专利> QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS AND AS MEDICAMENTS FOR THE PRODUCTION OF ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECTS IN WARM-BLOODED ANIMALS

QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS AND AS MEDICAMENTS FOR THE PRODUCTION OF ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECTS IN WARM-BLOODED ANIMALS

机译:喹唑啉衍生物,其制备方法,包含它们的药物组合物及其在药物制造中的用途,以及用于生产抗肿瘤药和/或在血管中降低血管渗透性的药物

摘要

The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is -O-, -NH- or -S-; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as defined herein; (ii) Q15W3 wherein Q15 and W3 are as defined herein, (iii) Q21W4C1-5alkylX1- wherein Q21, W4 and X1 are as defined herein, (iv) Q28C1-5alkylX1-, Q28C2-5alkenylX1- or Q28C2-5alkynylX1- wherein Q28 and X1 are as defined herein and (v) Q29C1-5alkylX1-, Q29C2-5alkenylX1- or Q29C2-5alkynylX1- wherein Q29 and X1 are as defined herein; R2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxy;and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm?blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
机译:本发明涉及式(I)化合物:其中环C如本文所定义,例如吲哚基,吲唑基或氮杂吲哚基; Z为-O-,-NH-或-S-; n为0-5; m为0-3; R1和R2在本文中定义为包括基团:(i)Q1X1,其中Q1和X1如本文所定义; (ii)Q15W3,其中Q15和W3如本文所定义,(iii)Q21W4C1-5烷基X1-,其中Q21,W4和X1如本文所定义,(iv)Q28C1-5烷基X1-,Q28C2-5烯基X1-或Q28C2-5炔基X1-,其中Q28和X1如本文所定义,和(v)Q29C1-5烷基X1-,Q29C2-5链烯基X1-或Q29C2-5炔基X1-,其中Q29和X1如本文所定义; R2也可以是6,7-亚甲基二氧基或6,7-亚乙基二氧基;及其盐;它们在制备用于在温血动物中产生抗血管生成和/或降低血管通透性的作用的药物中的用途;这类化合物的制备方法;此类过程中使用的中间体;这类中间体的制备方法;含有式I化合物或其药学上可接受的盐的药物组合物,以及通过施用式I化合物或其药学上可接受的盐来治疗涉及血管生成的疾病状态的方法。式I化合物抑制VEGF的作用,VEGF是治疗许多疾病包括癌症和类风湿关节炎的有价值的特性。

著录项

  • 公开/公告号IL163022B

    专利类型

  • 公开/公告日2012-10-31

    原文格式PDF

  • 申请/专利权人 ASTRAZENECA AB;

    申请/专利号IL163022

  • 发明设计人 LAURENT FRANCOIS ANDRE HENNEQUIN;

    申请日2004-07-14

  • 分类号C07D491/113;A61K31/517;A61K31/519;A61P9;A61P35;C07D401/14;C07D403/12;C07D403/14;C07D471/04;C07D491/04;C07D519;

  • 国家 IL

  • 入库时间 2022-08-21 17:24:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号